Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring
European Heart Journal - Cardiovascular Imaging · 23.08.2023 · 24 (9) · 1129-1145
DOI: 10.1093/ehjci/jead168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Heart Journal - Cardiovascular Imaging, online erschienen am 19.07.2023. Verfasst von Nidaa Mikail und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer and cardiovascular diseases (CVD) often share common risk factors, and patients with CVD who develop cancer are at high risk of experiencing major adverse cardiovascular events. Additionally, cancer treatment can induce short- and long-term adverse cardiovascular events. Given the improvement in oncological patients’ prognosis, the burden in this vulnerable population is slowly shifting towards increased cardiovascular mortality. Consequently, the field of cardio-oncology is steadily expanding, prompting the need for new markers to stratify and monitor the cardiovascular risk in oncological patients before, during, and after the completion of treatment. Advanced non-invasive cardiac imaging has raised great interest in the early detection of CVD and cardiotoxicity in oncological patients. Nuclear medicine has long been a pivotal exam to robustly assess and monitor the cardiac function of patients undergoing potentially cardiotoxic chemotherapies. In addition, recent radiotracers have shown great interest in the early detection of cancer-treatment-related cardiotoxicity. In this review, we summarize the current and emerging nuclear cardiology tools that can help identify cardiotoxicity and assess the cardiovascular risk in patients undergoing cancer treatments and discuss the specific role of nuclear cardiology alongside other non-invasive imaging techniques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
- Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland.
- Department of Nuclear Medicine, Bichat University Hospital, AP-HP, University Diderot, 75018 Paris, France.
- Nuclear Medicine, Institut de Cancérologie de Strasbourg Europe (ICANS), University Hospitals of Strasbourg, 67093 Strasbourg, France.
- Molecular Imaging-DRHIM, IPHC, UMR 7178, CNRS/Unistra, 67093 Strasbourg, France.
- Kantonsspital Glarus, Burgstrasse 99, 8750 Glarus, Switzerland.
ORCID-Profile: Nidaa Mikail, Susan Bengs, Alessia Gimelli
Zitieren
APA
Mikail, N., Chequer, R., Imperiale, A., Meisel, A., Bengs, S., Portmann, A., Gimelli, A., Buechel, R. R., Gebhard, C., & Rossi, A. (2023). Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring. European Heart Journal - Cardiovascular Imaging, 24(9), 1129-1145. https://doi.org/10.1093/ehjci/jead168
Vancouver
Mikail N, Chequer R, Imperiale A, Meisel A, Bengs S, Portmann A, et al. Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring. European Heart Journal - Cardiovascular Imaging. 2023;24(9):1129-1145. doi:10.1093/ehjci/jead168
BibTeX
@article{Mikail2023,
author = {Mikail, Nidaa and Chequer, Renata and Imperiale, Alessio and Meisel, Alexander and Bengs, Susan and Portmann, Angela and Gimelli, Alessia and Buechel, Ronny R and Gebhard, Cathérine and Rossi, Alexia},
title = {Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2023},
volume = {24},
number = {9},
pages = {1129--1145},
doi = {10.1093/ehjci/jead168}
}
EUVIMED